Effect of Carvedilol on Ambulatory Blood Pressure, Renal Hemodynamics, and Cardiac Function in Essential Hypertension

Dupont, Alain; Niepen, Patricia Van Der; Taeymans, Yves; Ingels, Michel; Piepsz, Amon; Bossuyt, Axel; Block, Pierre; Six, Roland; Jonckheer, Marc; Vanhaelst, L.

doi:10.1097/00005344-198710004-00024

Cited by 8 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With exercise, however, carvedilol-treated patients were able to increase the cardiac output in a similar fashion to those receiving placebo (derived from ref. 23). These data indicate preservation of myocardial performance with carvedilol treatment, in contrast to the effects observed with pure P-adrenoceptor blockers.…”

Section: Clinical Pharmacology and Hemodynamicsmentioning

confidence: 75%

“…In a randomized, double-blind, placebo-controlled study by Dupont et al (23), renal blood flow was maintained and renal vascular resistance was significantly decreased both acutely and after 4 weeks of carvedilol treatment. The glomerular filtration rate was slightly reduced acutely, but after 4 weeks of treatment had returned to baseline levels.…”

Section: Renal Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Carvedilol: A Novel Cardiovascular Drug with Multiple Actions

Ruffolo

Boyle

Brooks

et al. 1992

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Carvedilol (Fig. 1) is a novel multiple action drug that has recently been introduced to the market for the treatment of mild to moderate hypertension (7,8,2426). In extensive clinical trials conducted worldwide, comparisons to all major classes of antihypertensive agents, including captopril, nifedipine, and atenolol, have demonstrated that once-daily therapy with carvedilol is both highly efficacious and possesses a favorable side effect profile. Clinical trials are currently in progress to establish the utility of carvedilol in angina and congestive heart failure.Carvedilol is both a competitive P-adrenoceptor antagonist (76,93,94) and an arterial vasodilator (73). At higher concentrations, carvedilol is also a calcium channel antagonist (73,75,93,94). The vasodilatory actions result primarily from a,-adrenoceptor blockade (73,75,76), although in certain vascular beds, calcium channel blockade may also contribute to vasodilation (96,124). In addition to these actions on the heart and vasculature, carvedilol has also been shown to possess significant antioxidant and antiproliferative actions. These multiple actions are responsible for the antihypertensive efficacy of the drug in animals (93,94,105,106) and in humans (7,8,24-26), and may also work in conjunction to provide effective therapy in angina and congestive heart failure.The antihypertensive response produced by carvedilol is associated with a decrease in peripheral vascular resistance with either no change or only a moderate reduction in heart rate. The reduction in peripheral vascular resistance produced by carvedilol is indicative of arterial vasodilation (7,8,108), and the lack of reflex tachycardia is a direct consequence of the P-adrenoceptor blocking property of the drug (7).Carvedilol has been shown in animal models to protect all the major organ systems that comprise the cardiovascular system, specifically the kidney, heart, vasculature, and brain.

show abstract

Section: Clinical Pharmacology and Hemodynamicsmentioning

confidence: 75%

Section: Renal Effectsmentioning

confidence: 99%

Carvedilol: A Novel Cardiovascular Drug with Multiple Actions

Ruffolo

Boyle

Brooks

et al. 1992

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

show abstract

“…The maintenance of sodium excretion that occurs in animals treated with carvedilol contrasts with another pand a,-adrenoceptor antagonist, labetalol, which significantly reduces sodium excretion (18). This ability of carvedilol to maintain renal blood flow, glomerular filtration rate, and sodium excretion, which has been confirmed in human clinical trials (9), illustrates the important renal sparing effect of carvedilol that is not shared by most other antihypertensive agents.…”

Section: Renal Sparing Effects Of Carvedilolmentioning

confidence: 93%

Carvedilol: A Novel Multiple Action Antihypertensive Drug that Provides Major Organ Protection

Feuerstein

Yue

et al. 1994

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

“…3 Individual and statistical values (mean ± SEM) of aldosterone to renin ratio (ARR) (SAC to PRC ratio in pg / ml to pg / ml) in normotensive (NT) and hypertensive patients and patients with primary aldosteronism (PA) on different antihypertensive drug treatment regimens: # not significant, *P < 0·05, **P < 0·01, ***P < 0·001, all significances are related to group II (untreated hypertensive patients). ACEI, angiotensinconverting enzyme inhibitors; AT 1 , angiotensin II subtype 1. essential hypertension (Dupont et al, 1987;McKenna et al, 1991;Gallay et al, 2001). Others have found decreased aldosterone levels under short-term β-blocker medication (Blumenfeld et al, 1999).…”

Section: β-Blockersmentioning

confidence: 99%

Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism

Seifarth¹,

Trenkel

Schobel

et al. 2002

Clinical Endocrinology

151

View full text Add to dashboard Cite

Beta-blockers and aldosterone antagonists have the strongest impact on the renin-angiotensin system. The decrease in renin concentration by beta-blockers leads to an increase in the ratio of aldosterone to renin, and thus to false-positive results in patients with essential hypertension. Calcium channel blockers, and probably also ACE inhibitors and AT1 receptor antagonists alone or in combination, may be continued during screening for primary aldosteronism by determination of renin and aldosterone concentration.

show abstract

Effect of Carvedilol on Ambulatory Blood Pressure, Renal Hemodynamics, and Cardiac Function in Essential Hypertension

Cited by 8 publications

References 0 publications

Carvedilol: A Novel Cardiovascular Drug with Multiple Actions

Carvedilol: A Novel Cardiovascular Drug with Multiple Actions

Carvedilol: A Novel Multiple Action Antihypertensive Drug that Provides Major Organ Protection

Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism

Contact Info

Product

Resources

About